While nearly 60% of biopharma leaders report doubling their ROI from AI initiatives within a year, less than 5% consider their organizations fully mature in using AI for marketing and sales.
To overcome challenges like scaling and siloing, pharma marketers can now leverage highly targeted, AI-driven optichannel strategies. Derek Choy recently explored this in depth in Pharmaphorum.
Key takeaways include:
- Invest in end-to-end systems: Success requires an end-to-end, AI-powered system rather than piecemeal solutions that have to be patched together. Unified systems could eventually reduce commercial planning and execution timelines from 18 months down to as little as six.
- Shift from omnichannel to optichannel: Instead of buying media everywhere, AI and machine learning make rapid, data-driven decisions achievable. Teams can invest strictly where data predicts the highest resonance, allowing for decisions, deployments, and optimizations within 24 hours of receiving new information.
- Dynamic, real-time adjustments: AI allows teams to quickly respond to real-world signals (like diagnosis or mutation test data) and dynamically adjust the media mix, channel selections, and rep recommendations. Embedding these predictive recommendations directly into CRM workflows has been shown to improve rep adherence to brand strategy by 22%.
- Prioritize transparency: A system is only as good as the data it learns from. To support teams effectively and meet strict compliance standards, attention to data sources is critical. And transparency and auditable explainability of the AI’s recommendations are non-negotiable.
- Deliver proven ROI: Optichannel approaches are proven to deliver a 3x average script lift, an 80% increase HCP engagement rates, and 20-30% budget savings compared to traditional models.
When deployed correctly, AI empowers marketers to deliver hyper-personalized HCP journeys at scale, unifying brand and field teams to achieve unprecedented business outcomes.